News|Articles|June 30, 2026

5 FDA Decisions for Primary Care to Know from June 2026

Recent FDA actions include updates on COVID-19 prophylaxis, ADHD, PTSD neuromodulation, and pediatric psoriasis and psoriatic arthritis care.

In June, the US Food and Drug Administration (FDA) issued several regulatory decisions with potential relevance across primary care, dermatology, infectious disease, and behavioral health. The updates included a first-in-class oral postexposure prophylaxis option for COVID-19, a Complete Response Letter for an investigational ADHD therapy, and clearance of a personalized neuromodulation platform for post-traumatic stress disorder.

Related to this article

September 29th, 2026

FDA Grants Priority Review to Elinzanetant for VMS in HR+ Breast Cancer Patients on Endocrine Therapy

The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.

September 28th, 2026

FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata

The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.

FDA Approves Insulin Efsitora Alfa-Gobe, First Once-Weekly Basal Insulin for Type 2 Diabetes / image credit: MJH Life Sciences

September 24th, 2026

FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes

The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.

September 22nd, 2026

FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH

FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.

September 17th, 2026

FDA Approves Finerenone for CKD Associated With Type 1 Diabetes

Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.

September 15th, 2026

FDA Clears Beta Bionics’ Mint Reusable Insulin Patch Pump

The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.

September 14th, 2026

FDA Accepts Extended Duration sNDA for Miudella Hormone-Free IUD

The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.

September 8th, 2026

FDA Grants Breakthrough Therapy Designation to DT120 for Major Depressive Disorder

FDA awarded DT120 Breakthrough Therapy designation for MDD based on phase 3 data showing rapid, sustained improvement after one 100 μg dose.